Navigation Links
Damon Runyon Cancer Research Foundation awards prestigious fellowships to 13 top young investigators
Date:2/24/2009

New York, NY-- The Damon Runyon Cancer Research Foundation named 13 new Damon Runyon Fellows at its November 2008 Fellowship Award Committee review. The recipients of this prestigious, three-year award are outstanding postdoctoral scientists conducting basic and translational cancer research in the laboratories of leading senior investigators across the country. The Fellowship is specifically intended to encourage the nation's most promising young investigators to pursue careers in cancer research by providing them with independent funding to work on innovative projects. The Damon Runyon Cancer Research Foundation has committed more than $200 million to support the careers of cancer researchers across the United States since the program's inception.

November 2008 Damon Runyon Fellows:

  • Christopher S. Campbell, PhD, with his sponsor Arshad B. Desai, PhD, at the University of California, San Diego, California, is studying regulatory mechanisms that prevent instability of the genome. His research will aid in our understanding of how disruption of these processes can lead to cancer.

  • Oscar R. Colegio, MD, PhD, with his sponsor Ruslan M. Medzhitov, PhD, at Yale University, New Haven, Connecticut, is studying the role of immune cells called macrophages in tumor progression and metastasis (cancer spread). His goal is to identify and characterize molecular pathways critical to metastatic cancers, particularly lung, breast, and skin cancers. These studies may lead to novel therapeutic targets to limit or prevent metastasis.

  • Jason Michael Crawford, PhD, with his sponsor Jon Clardy, PhD, at Harvard Medical School, Boston, Massachusetts, is developing DNA-based methods to discover novel compounds from microbes, such as bacteria and fungi, towards the development of improved anticancer therapeutics.

  • William J. Greenleaf, PhD, with his sponsor X. Sunney Xie, PhD, at Harvard University, Cambridge, Massachusetts, is developing highly-sensitive fluorescence assays that will allow observation of single molecules of individual enzymes, providing insight into how cellular machinery may malfunction in cancers.

  • William Rodney Hardy, PhD, with his sponsor Michael R. Green, MD, PhD, at the University of Massachusetts Medical School, Worcester, Massachusetts, is studying a process called oncogene-induced senescence, which stops tumor cell development thus protecting the body against cancer. His goals are to improve our understanding of this process. Dr. Hardy hopes to reveal ways by which oncogene-induced senescence can be exploited as a treatment for cancer.

  • Kristina M. Herbert, PhD, with her sponsor Joan A. Steitz, PhD, at Yale University, New Haven, Connecticut, is studying the mechanism by which small RNAs called microRNAs are produced and the regulation of this process within the cell. She hopes to gain understanding of why certain microRNAs are expressed at low levels in cancers.

  • Simon Jenni, PhD, with his sponsor Stephen C. Harrison, PhD, at Harvard Medical School, Boston, Massachusetts, is studying the structure of kinetochores, protein complexes that mediate the segregation of chromosomes during cell division. Discrepancies in the distribution of chromosomes in divided cells occur in many cancers and diseases such as Down's syndrome. The research will provide a firmer foundation for our understanding of cancer and identify potential avenues for anticancer therapies.

  • Jung-Min Kee, PhD, with his sponsor Thomas W. Muir, PhD, at The Rockefeller University, New York, New York, is attempting to elucidate the mechanism and function of histidine phosphorylation, a particular type of protein modification that can be linked to liver cancer. He is developing novel research tools by combining synthetic chemistry and biology, which could ultimately lead to new and more effective cancer treatments.

  • Young Kwon, PhD, with his sponsor Norbert Perrimon, PhD, at Harvard Medical School, Boston, Massachusetts, is aiming to discover new regulators of the insulin signaling pathway that keep the pathway "in check" during cellular growth. As multiple negative regulators of insulin signaling are already known to function in tumor suppression, this study may lead to the identification of new tumor suppressor pathways.

  • Ken S. Lau, PhD, with his sponsors Kevin M. Haigis, PhD, and Douglas A. Lauffenburger, PhD, at Massachusetts General Hospital, Boston, Massachusetts, is working to identify new protein networks that interact with the oncogenic Ras signaling pathway, which is rewired in over half of colorectal cancer cases. Targeting these new interactions in combinatorial therapy may become an effective way to manage this deadly disease in the future.

  • Tiffany Reese, PhD, with her sponsor Herbert W. Virgin, MD, PhD, at Washington University, Saint Louis, Missouri, is exploring how the immune system recognizes persistent viral infections. Because these viruses persist for the life of the host and cause lymphomas and tumors in immunocompromised hosts, understanding the intricate balance between viral persistence and immune control is fundamentally important to elucidating mechanisms of virally-induced cancer.

  • Xu Tan, PhD, with his sponsor Stephen J. Elledge, PhD, at Brigham and Women's Hospital, Boston, Massachusetts, is studying the role of the BRCA1 gene, which has been linked to familial breast cancer. His goal is to identify genes that act in concert with BRCA1, which could explain the specific effect of BRCA1 mutations on breast tissue carcinogenesis.

  • Jesse Zalatan, PhD, with his sponsor Wendell A. Lim, PhD, at University of California, San Francisco, California, is studying how specificity is maintained in cell signaling networks, with a particular focus on the role of molecules called scaffold proteins in MAP kinase signaling pathways. Defects in these pathways are often associated with cancer and other physiological disorders.


'/>"/>

Contact: Yung S. Lie, Ph.D.
awards@damonrunyon.org
212-455-0520
Damon Runyon Cancer Research Foundation
Source:Eurekalert

Related biology news :

1. Damon Runyon Cancer Research Foundation awards prestigious fellowships to 17 top young investigators
2. BIDMC scientist John Rinn, Ph.D., receives Damon-Runyon Rachleff Innovation Award
3. 2009 Damon Runyon-Rachleff Innovation Awards granted for pioneering ideas in cancer research
4. Green tea boosts production of detox enzymes, rendering cancerous chemicals harmless
5. A study by the MUHC and McGill University opens a new door to understanding cancer
6. ESF EURYI award winner aims to stop cancer cells reading their own DNA
7. Protein chatter linked to cancer activation
8. Newly created cancer stem cells could aid breast cancer research
9. Western diet linked to increased risk of colon cancer recurrence
10. Obesity and lack of exercise could enhance the risk of pancreatic cancer
11. Low levels of key protein may indicate pancreatic cancer risk
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2016)... 20, 2016  VoiceIt is excited to announce ... By working together, VoiceIt and VoicePass ... and VoicePass take slightly different approaches to voice ... security and usability. ... new partnership. "This marketing and technology ...
(Date:5/12/2016)... May 12, 2016 WearablesResearch.com , a ... the overview results from the Q1 wave of its ... wave was consumers, receptivity to a program where they ... a health insurance company. "We were surprised ... says Michael LaColla , CEO of Troubadour Research, ...
(Date:5/3/2016)... 3, 2016  Neurotechnology, a provider of high-precision ... Automated Biometric Identification System (ABIS) , a complete ... MegaMatcher ABIS can process multiple complex biometric transactions ... of fingerprint, face or iris biometrics. It leverages ... and MegaMatcher Accelerator , which have been ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... FRANCISCO , June 23, 2016   EpiBiome ... has secured $1 million in debt financing from Silicon ... ramp up automation and to advance its drug development ... its new facility. "SVB has been an ... beyond the services a traditional bank would provide," said ...
(Date:6/23/2016)...  Blueprint Bio, a company dedicated to identifying, protecting ... has closed its Series A funding round, according to ... "We have received a commitment from Forentis Fund that ... meet our current goals," stated Matthew Nunez . ... complete validation on the current projects in our pipeline, ...
(Date:6/23/2016)... ... June 23, 2016 , ... Velocity Products, ... tools designed, tuned and optimized exclusively for Okuma CNC machining centers at The ... of a collaboration among several companies with expertise in toolholding, cutting tools, machining ...
(Date:6/22/2016)... NEW YORK , June 22, 2016 /PRNewswire/ ... the growing next generation sequencing (NGS) market include ... adoption of smaller sequencers.  More accessible and affordable ... led to growing demand for consumables including sample ... The Market for Sample Preparation for Next ...
Breaking Biology Technology: